Kalzium- und Vitamin-D-Substitution bei Osteoporose
Standard
Kalzium- und Vitamin-D-Substitution bei Osteoporose : Nutzen oder Risiko. / Ringe, J. D.; Windler, E.
in: GYNAKOL ENDOKRINOL, Jahrgang 13, Nr. 1, 17.02.2015, S. 11-15.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Kalzium- und Vitamin-D-Substitution bei Osteoporose
T2 - Nutzen oder Risiko
AU - Ringe, J. D.
AU - Windler, E.
N1 - Publisher Copyright: © 2014, Springer-Verlag Berlin Heidelberg.
PY - 2015/2/17
Y1 - 2015/2/17
N2 - Insufficient calcium intake results in increased bone resorption leading to osteoporosis. In this situation a normal serum calcium level is maintained at the cost of the skeleton, i.e. development of secondary hyperparathyroidism. Vitamin D enhances intestinal calcium absorption and osteoid mineralization and reduces parathyroid hormone secretion. Therefore, calcium and vitamin D supplements are generally recommended for prevention and as a basic therapy of osteoporosis. When dosing these supplements nutritional calcium and vitamin D synthesis during sun exposure have to be taken into consideration. It is also important to take into consideration that calcium intake and intestinal absorption as well as vitamin D production decrease with increasing age. Calcium intake should be in the range of 1000–1500 mg and vitamin D 800–2000 IU per day or 25-hydroxy-vitamin D plasma levels between 30 and 50 ng/ml. With these dosages hypercalcemia and hypercalciuria are extremely rare adverse events and the risk of kidney stones is very low. Communications of increased cardiovascular events related to long-term calcium or calcium and vitamin D intake induced a significant reduction of prescriptions of corresponding preparations. Other publications, however, communicated cardioprotective effects of vitamin D and recent publications could not confirm an increased risk of cardiovascular events with calcium alone or in combination with vitamin D and even demonstrated reduced mortality. Until final clarification of these discrepant study results a regular moderate intake of calcium and vitamin D supplements within the abovementioned dosage range is recommended.
AB - Insufficient calcium intake results in increased bone resorption leading to osteoporosis. In this situation a normal serum calcium level is maintained at the cost of the skeleton, i.e. development of secondary hyperparathyroidism. Vitamin D enhances intestinal calcium absorption and osteoid mineralization and reduces parathyroid hormone secretion. Therefore, calcium and vitamin D supplements are generally recommended for prevention and as a basic therapy of osteoporosis. When dosing these supplements nutritional calcium and vitamin D synthesis during sun exposure have to be taken into consideration. It is also important to take into consideration that calcium intake and intestinal absorption as well as vitamin D production decrease with increasing age. Calcium intake should be in the range of 1000–1500 mg and vitamin D 800–2000 IU per day or 25-hydroxy-vitamin D plasma levels between 30 and 50 ng/ml. With these dosages hypercalcemia and hypercalciuria are extremely rare adverse events and the risk of kidney stones is very low. Communications of increased cardiovascular events related to long-term calcium or calcium and vitamin D intake induced a significant reduction of prescriptions of corresponding preparations. Other publications, however, communicated cardioprotective effects of vitamin D and recent publications could not confirm an increased risk of cardiovascular events with calcium alone or in combination with vitamin D and even demonstrated reduced mortality. Until final clarification of these discrepant study results a regular moderate intake of calcium and vitamin D supplements within the abovementioned dosage range is recommended.
KW - Calcium, dietary
KW - Cardiovascular diseases
KW - Dietary supplements
KW - Falls
KW - Fractures
UR - http://www.scopus.com/inward/record.url?scp=84925532795&partnerID=8YFLogxK
U2 - 10.1007/s10304-014-0644-0
DO - 10.1007/s10304-014-0644-0
M3 - SCORING: Zeitschriftenaufsatz
AN - SCOPUS:84925532795
VL - 13
SP - 11
EP - 15
JO - GYNAKOL ENDOKRINOL
JF - GYNAKOL ENDOKRINOL
SN - 1610-2894
IS - 1
ER -